After the (draft) sequence

Now that the dust has settled after publication of the human genome sequence, Sydney Brenner assesses the first draft.

Written bySydney Brenner
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

We now have the two reports on the human genome sequence, one, in Nature by the International Human Genome Sequencing Consortium (GC), the other, in Science by Celera Genomics (CG). Each is accompanied by a flurry of secondary papers analyzing different aspects of the sequence, and these will no doubt be followed in the future by more analyses as, at least, the public sequence is available with no restrictions whatsoever to those who wish to examine it. The amount of information is enormous and all we have here is the surface. I have spent some time on both papers but the material will require much deeper reading in months to come.

I will begin by saying something about the two approaches used. GC based their approach on sequencing ordered, large-insert bacterial artificial chromosome (BAC) libraries which had previously been shown to produce data with 99.99% accuracy and no gaps. It ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies